A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 810 participants.

Also called NCT04951219

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 810 participants (enrolled count) (from the registry)
Sponsor
Madrigal Pharmaceuticals, Inc. (from the registry)
Registry
  • NCT NCT04951219
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Puerto Rico (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT04951219. Randomized; triple masking; primary purpose treatment. Start 2021-07-09 (actual); primary completion 2027-03 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
Condition
Non-Alcoholic Fatty Liver Disease
Intervention (Drug)
Resmetirom
Lead sponsor
Madrigal Pharmaceuticals, Inc. (class: industry)

Record details

Record id
cardio:ct-nct04951219
Content hash
5d32474795859dbdea3398eab3d1801d8c69f2fc27c7f6f835b17505b58ba4c5